Evidence map›Paper›PMID 19405107›Full record

ArticleJournal of neuroscience research2009

A novel inducible tyrosine kinase receptor to regulate signal transduction and neurite outgrowth.

Ronald W Alfa, Mark H Tuszynski, Armin Blesch

Open access · greenAbstract read
In one paragraph

Article in Journal of neuroscience research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Optical Activation of TrkA Signaling.ACS synthetic biology · 2018
    Article
  4. Article
  5. Article
  6. Oligodendrocyte-specific activation of PERK signaling protects mice against experimental autoimmune encephalomyelitis.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2013
    Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ronald W AlfaDepartment of Neurosciences-0626, University of California, San Diego, La Jolla, California 92093-0626, USA.
Mark H Tuszynski
Armin Blesch
University of California, San Diego · US

Funding

U of Calif, San Diego Neuroscience Microscopy ImagingP30NS047101 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GLEESON, JOSEPH G, ZHENG, BINHAI · 2003 to 2022
$9.0M
Regulatable Gene Transfer for Spinal Cord InjuryR01NS054883 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BLESCH, ARMIN · 2007 to 2010
$920k
Regulatable Gene Therapy for Axonal RegenerationR21NS046466 · NINDS · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI BLESCH, ARMIN · 2004 to 2005
$352k
MINORITY PREDOCTORAL FELLOWSHIP PROGRAM--NIGMSF31NS009881 · NINDS · UNIVERSITY OF TEXAS EL PASO · PI BOGGIANO, MARY M · 1994 to 1997
–
NINDS NIH HHS F31 NS009881NINDS NIH HHS NS047101NINDS NIH HHS NS09881NINDS NIH HHS NS46466NINDS NIH HHS NS54833NINDS NIH HHS P30 NS047101NINDS NIH HHS R01 NS054883NINDS NIH HHS R21 NS046466
6 · The paper itself

Abstract

Nervous system growth factor gene delivery can promote axonal growth and prevent cell death in animal models of CNS trauma and neurodegenerative diseases. The ability to regulate growth factor expression or signaling pathways downstream from growth factor receptors remains a desirable goal for in vivo gene transfer. To achieve precise pharmacological modulation of neurotrophin activity, we have generated a chimeric trkA receptor (ItrkA) by fusing the entire intracellular domain of the trkA high-affinity NGF receptor to two intracellular, modified FK506 binding domains for the synthetic small molecule dimerization ligand AP20187. Rat PC12 cells were transduced with lentiviral vectors containing ItrkA and green fluorescent protein (GFP; via an internal ribosome entry site). Treatment of ItrkA-expressing PC12 cells with AP20187 induced neurite outgrowth and differentiation in a time- and dose-dependent fashion, with a half-maximal response at a concentration of 1 nM AP20187. Seventy percent of cells responded to AP20187 by day 3. Western blots demonstrated that AP20187 treatment resulted in phosphorylation of Erk1/2 and Akt in ItrkA-transduced PC12 cells but not in nontransduced, naïve cells. Phosphorylation levels were comparable to levels obtained with 50 ng/ml nerve growth factor (NGF). In addition, ItrkA lentiviral transduction of primary E15 dorsal root ganglion neurons significantly increased neurite growth three- to fourfold in the presence of AP20187 compared with control GFP transduced and naïve neurons. These results demonstrate that small ligand-induced dimerization of the intracellular domain of trkA can efficiently simulate the biological activity of NGF and provide a means to regulate intracellular neurotrophin receptor signaling.

Indexed as

AnimalsCell DifferentiationDose-Response Relationship, DrugGanglia, SpinalGenetic VectorsMitogen-Activated Protein Kinase 3Mutant Chimeric ProteinsNerve Growth FactorNervous SystemNeuritesNeurogenesisPC12 CellsPhosphorylationProtein BindingProtein Structure, TertiaryProto-Oncogene Proteins c-aktAP20187Mitogen-Activated Protein Kinase 3Mutant Chimeric ProteinsNerve Growth FactorProto-Oncogene Proteins c-aktReceptor, trkARecombinant Fusion ProteinsTacrolimus

Identifiers

PMID19405107
PMCPMC2854653
OpenAlexW2045762797

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.